Xeltis attends VEITHsymposium 2026 in New York
Its CEO and other executives will connect with clinicians and partners, while two professors present on its restorative vascular implants, including aXess for hemodialysis.
See the latest news and media coverage for Xeltis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical technology company developing regenerative vascular implants
xeltis.comLast updated
In short: Xeltis raised €20.5 million to advance aXess toward FDA approval and a US launch
Its CEO and other executives will connect with clinicians and partners, while two professors present on its restorative vascular implants, including aXess for hemodialysis.
He brings over 20 years of medtech and pharma experience, joining from Getinge, and will drive clinical strategy ahead of US market entry.
CEO Eliane Schutte accepted the honour at the EIB TechEU Equity Summit and joined a panel on financing scale-ups.
She will lead US commercial readiness and business development for the aXess vascular access implant, after helping deliver its European launch.
The MarketWatch News Department was not involved in the creation of this content. -- CE mark awarded for aXess(TM) at record speed, underpinned by strong...
Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m €10m investment from existing shareholders...
Xeltis has announced successful results from its aXess EU phase 3 trial, confirming the potential of its restorative vascular access conduit for patients undergoing hemodialysis...
Xeltis' polymer-based heart valve is designed to let the body naturally restore heart valve function before it is absorbed into the body. Xeltis, which is...
Track Xeltis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.